FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
Amedisys (NASDAQ: AMED) reported Q4 EPS of $1.16, $0.18 better than the analyst estimate of $0.98. Revenue for the quarter came in at $562 million versus the consensus estimate of $560.59 million.
GUIDANCE:
Amedisys sees FY2023 EPS of $4.13-$4.36, versus the consensus of $4.86. Amedisys sees... More

